Bailard’s Cartesian Therapeutics RNAC Stock Holding History

Bailard’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,740	Closed	-$86K	–	773
2022 Q3	$86K	Buy	1,740 +73	+4%	+$4.01K	﹤0.01%	639
2022 Q2	$66K	Buy	+1,667	New	+$49.4K	﹤0.01%	669

Other funds holding RNAC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bailard's RNAC Position: Q4 2022 in Review

Bailard sold out of Cartesian Therapeutics (RNAC) in Q4 2022, closing a stake of 1,740 shares — an estimated $86K sold.

Bailard first reported a position in RNAC in Q2 2022 and held it in 2 quarters. The position peaked at $86K in Q3 2022. 84 funds tracked by Wall St. Rank hold RNAC as of Q4 2022.

Bailard reported no remaining Cartesian Therapeutics position as of Q4 2022 after selling out during the quarter.
Bailard sold 1,740 Cartesian Therapeutics shares in Q4 2022, an estimated $86K.
Bailard first reported a position in Cartesian Therapeutics in Q2 2022 and held it in 2 quarters.
Bailard's Cartesian Therapeutics position peaked at $86K in Q3 2022.
84 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2022.

Based on Bailard's 13F filing for Q4 2022, filed 2 Feb 2023.